LDL Cholesterol Reduction Following Ezetimibe Initiation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07839741

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07839741
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Portugal (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07839741. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2027-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LDL Cholesterol Reduction Following Ezetimibe Initiation
Acronym
EZE-TRACK
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Condition
Cardiovascular Risk
Intervention (Drug)
Ezetimibe
Lead sponsor
Universidade do Porto (class: other)

Record details

Record id
cardio:ct-nct07839741
Content hash
f7e2051c4e539d7635e5c8925dc880fd39c54d3f1c4128ecdfa8a3d5280e739e